Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

In a move to enhance affordability and ensure price regulation of essential medicines, the Government of India has confirmed ...

The Central Drugs Standard Control Organisation (CDSCO) has launched a new QR code-based online appointment system to ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that ...

Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of ...